SEARCH

SEARCH BY CITATION

  • 1
    Bryans JR, Fallon EH, Shephard BP. Equine salmonellosis. Cornell Vet 1961; 51:467477.
  • 2
    Carroll EJ, Schalm OW, Wheat JD. Endotoxemia in a horse. J Am Vet Assoc 1965; 146:13001303.
  • 3
    McClure JJ. Endotoxic shock. Vet Clin North Am 1976; 6:193202.
  • 4
    Moore JN. Recognition and treatment of endotoxemia. Vet Clin North Am Equine Pract 1988; 4:105113.
  • 5
    Moore JN, Garner HE, Berg JN, et al. Intracecal endotoxin and lactate during the onset of equine laminitis: A preliminary report. Am J Vet Res 1979; 40:722723.
  • 6
    Van Deventer SJH, Cate JH, Tytgat GNJ. Intestinal endotoxemia: Clinical significance. Gastroenterology 1988; 94:825831.
  • 7
    Moore JN, White NA, Berg JN, et al. Endotoxemia following experimental intestinal strangulation obstruction in ponies. Can J Comp Med 1981; 45:330332.
  • 8
    McClure JJ, McClure JR, Johnson DW. Detection of endotoxin in the blood and peritoneal fluid of ponies with experimentally created strangulation obstruction of the small intestine. Proc Annu Meet Am Assoc Equine Pract 1982; 1:102108.
  • 9
    Meyers K., Reed S., Keck M., et al. Circulating endotoxin-like substance(s) and altered hemostasis in horses with gastrointestinal disorders: An interim report. Am J Vet Res 1982; 43:22332238.
  • 10
    Woolcock JB. Pathogenesis of bacterial infections: Some determinants of virulence in gram-negative bacteria. Aust Vet J 1985; 62:177181.
  • 11
    Ziegler EJ. Extraintestinal infections caused by enteric bacteria. In: WyngaardenJB, SmithLH, eds. Cecil Textbook of Medicine. 18th ed. Philadelphia : WB Saunders, 1988; 16581661.
  • 12
    Rietschel EV, Schade V., Jensen M., et al. Bacterial endotoxins: Chemical structure, biological activity and role in septicemia. Scand J Infect Dis Suppl 1982; 31:821.
  • 13
    McCabe WR, Treadwell TL, DeMaria A., Jr. Pathophysiology of bacteremia. Am J Med 1983; 75:718.
  • 14
    Luderitz O., Tannamoto K., Galanos C., et al. Lipopoiysaccharides: Structural principles and biologic activities. Rev Infect Dis 1984; 6:428431.
  • 15
    Sprouse RF, Garner HE, Green EM. Active and passive immunization against endotoxemia. Proc 6th Annu Vet Med Forum. Washington, DC 1988; 329331.
  • 16
    King JN, Gerring EL. Detection of endotoxemia in cases of equine colic. Vet Rec 1988; 123:269271.
  • 17
    Burrows GE. Equine Escherichia coli endotoxemia: comparison of intraperitoneal endotoxin administration. Am J Vet Res 1979; 40:991998.
  • 18
    Moore JN, Garner HG, Shapland GE, et al. Lactic acidosis and arterial hypoxemia during sublethal endotoxemia in conscious ponies. Am J Vet Res 1980; 41:16961698.
  • 19
    Morris DD, Whitlock RH, Corbeil LB. Endotoxemia in horses: Protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 1986; 47:544550.
  • 20
    White NA, Moore JN, Cowgill LM, et al. Epizootiology and risk factors in equine colic at a university hospital. In: MooreJN, WhiteNA, BechtJL, eds. Proceed 2nd Equine Col Res Sympos, Lawrenceville , NJ : Vet Learning Systems, 1986; 2629.
  • 21
    Koterba AM, Brewer BD, Tarplee FA. Clinical and clinicopathological characteristics of the septicemic neonatal foal: Review of 38 cases. Equine Vet J 1984; 16:376383.
  • 22
    Morris DD. Bacterial infection in the newborn foal. Part I. Clinical presentation, laboratory findings and pathogenesis. Comp Com Educ Pract Vet 1984; 8:S332S339.
  • 23
    Baker SM, Drummond WH, Lane TJ, et al. Follow-up evaluation of horses after neonatal intensive care. J Am Vet Med Assoc 1986; 189:14541457.
  • 24
    Baxter GM. Equine laminitis caused by distal displacement of the distal phalanx: 12 cases (1976–1985). J Am Vet Med Assoc 1986; 189:326329.
  • 25
    Morris DD. Recognition and management of disseminated intravascular coagulation in horses. Vet Clin North Am Equine Pract 1988; 4:115143.
  • 26
    Rossdale PD, Hopes R., Wingfield Digby NJ, et al. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 1985; 116:6669.
  • 27
    Merkt H., von Lepel J. Report on the autumn 1970 examinations of West German Thoroughbreds (bloodstock). Vollblut Zucht Rennen 1971; 34:2630.
  • 28
    McCue JD. Improved mortality in gram-negative bacillary bacteremia. Arch Intern Med 1985; 145:12121216.
  • 29
    Shenep JL, Flynn PM, Barrett FF, et al. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157:565568.
  • 30
    Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol 1978; 73:526616.
  • 31
    Peavy DL, Brandon CL. Macrophages: Primary targets for LPS activity. In: AgarwalML, ed. Bacterial Endotoxins and Host Response. New York : Elsevier-North Holland Biomedical Press, 1980; 299309.
  • 32
    Maier RV, Ulevitch RJ. The response of isolated rabbit macrophages to lipopolysaccharide (LPS). Circ Shock 1981; 8:165181.
  • 33
    Cook J. A., Halushka PV, Wise WC. Modulation of macrophage arachidonic acid metabolism: Potential role in the susceptibility of rats to endotoxic shock. Circ Shock 1982; 9:605617.
  • 34
    Maier RV, Hahnel GB. Is macrophage-induced microthrombosis during endotoxemia dependent on prostaglandin synthesis J Surg Res 1986; 40:238247.
  • 35
    McCuskey RS, McCuskey PA, Urbaschek R., et al. Species differences in Kupffer cells and endotoxin sensitivity. Infect Immun 1984; 45:278280.
  • 36
    Watson JK, Kelly K., Largen M., et al. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immun 1978; 120:422424.
  • 37
    Williams Z., Hertogo CF, Plaznik DN. Use of mice tolerant to lipopolysaccharide to demonstrate requirement of cooperation between macrophages and lymphocytes to generate lipopolysaccharde-induced colony-stimulating factor in vivo. Infect Immun 1983; 41:15.
  • 38
    Johnston CA, Greisman SE. Mechanism of endotoxin tolerance. In: HinshawLB (ed.). Handbook of Endotoxin. Vol 2: Pathophysiology of Endotoxin. New York : Elsevier Science, 1985; 359.
  • 39
    Nolan JP, Hare DK, McDevitt JJ, et al. In vitro studies of intestinal endotoxin absorption. Gastroenterology 1977; 72:434439.
  • 40
    Jacob AI, Goldberg PK, Bloom N., et al. Endotoxin and bacteria in portal blood. Gastroenterology 1977; 72:12681278.
  • 41
    Caruana JA, Camara DS, Schneeberger GJ, et al. The clearance capacity of the canine liver for a portal vein endotoxin infusion. J Surg Res 1984; 37:197201.
  • 42
    Bradfield JWB. Control of spillover: The importance of the Kupffer-cell function in clinical medicine. Lancet 1974; 2:883885.
  • 43
    Triger DR, Boyer TD, Levin J. Portal and systemic bacteremia and endotoxemia in liver disease. Gut 1978; 19:935939.
  • 44
    Gathiram P., Wells MT, Raidpo D., et al. Changes in lipopolysaccharide concentrations in hepatic portal and systemic arterial plasma during intestinal ischemia in monkeys. Circ Shock 1989; 27:103109.
  • 45
    Kelley CJ, Ingoldby CJH, Blenkhorn JI, et al. Colonoscopy related endotoxaemia. Surg Gynecol Obstet 1985; 161:332334.
  • 46
    Gaffin SL, Wells M., Jordan JP. Anti-LPS toxin therapy for whole body x-irradiation overdose. Br J Radiol 1985; 58:881884.
  • 47
    Deitch EA, Maejima K., Berg R. Effects of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in rats. J Trauma 1985; 25:385392.
  • 48
    Schoeffel U., Windfuhr M., Freudenberg N., et al. The role of intestinal endotoxin in experimental peritonitis. Circ Shock 1989; 27:8391.
  • 49
    Nozickova M., Barton V., Sedlak J. Effect of transient intestinal ischemia on the thoracic duct lymph absorption of endotoxin. Lymphology 1977; 11:161165.
  • 50
    Olofsson P., Nylander G., Olsson P. Endotoxin-transport routes and kinetics in intestinal ischemia. Acta Chir Scand 1985; 151:635639.
  • 51
    Gathiram P., Wells MT, Raidoo D., et al. Portal and systemic plasma lipopolysaccharide concentrations in heat-stressed primates. Circ Shock 1988; 25:223230.
  • 52
    Karakusis PH. Considerations in the therapy of septic shock. Med Clin North Am 1986; 70:933944.
  • 53
    Muller-Berghaus G. Septicemia and the vessel wall. In: VerstraeteM., (ed.) Thrombosis and hemostasis 1987. Leuven Belgium : Leuven Univ Press, 1987; 619671.
  • 54
    Lindsay SS, Wheeler B., Sanderson KE, et al. The release of alkaline phosphatase and of lipopolysaccharide during the growth of rough and smooth strains of Salmonella typhymurium. Can J Microbiol 1972; 19:335343.
  • 55
    Hoekstra D., Van der Laan JW, DeLey L., et al. Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta 1976; 455:889899.
  • 56
    Braude AI, Jones JL, Douglas H. The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. J Immunol 1963; 90:297311.
  • 57
    Nowotny A. Molecular aspects of endotoxic reactions. Bacteriol Rev 1969; 33:7298.
  • 58
    McCabe WR. Immunization with R mutants of S minnesota; I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972; 108: 601610.
  • 59
    Davis CE, Ziegler EJ, Arnold K. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med 1978; 147:10071017.
  • 60
    Ziegler EJ, McCutchan JA, Fierer J., et al. Treatment of gramnegative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:12251230.
  • 61
    Johns M., Skehill A., McCabe WR. Immunization with rough mutants of Salmonella minnesota: IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis 1983; 147: 5767.
  • 62
    Braude AI, Douglas H., Davis CE. Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J Infect Dis 1973; 128:S157S164.
  • 63
    Hinshaw LB, Benjamin B., Holmes DD, et al. Responses of the baboon to live Escherichia coli organisms and endotoxin. Surg Gynecol Obstet 1977; 145:111.
  • 64
    Jacobs ER, Soulsby ME, Bone RC, et al. Ibuprofen in canine endotoxin shock. J Clin Invest 1982; 70:536541.
  • 65
    Hinshaw LB. Application of animal shock models to the human. Circ Shock 1985; 11:205212.
  • 66
    Morris DD, Cullor JS, Whitlock RH, et al. Endotoxemia in neonatal calves given antiserum to a mutant Escherichia coli (J-5). Am J Vet Res 1986; 47:25542565.
  • 67
    Ward DS, Fessler JF, Bottoms GD, et al. Equine endotoxemia: Cardiovascular, eicosanoid, hematologic, blood chemical, and plasma enzyme alterations. Am J Vet Res 1987; 48:11501156.
  • 68
    Pearson FC, Dubczak J., Weary M., et al. Detection of endotoxin in the plasma of patients with gram-negative bacterial sepsis by the limulus amoebocyte lysate assay. J Clin Microbiol 1985; 21:865868.
  • 69
    McCartney AC, Piotrowicz BI, Edlin SE, et al. Evaluation of the chromogenic limulus lysate assay in septic shock. In: WatsonSW, LevinJ., NovitskyTJ (eds.) Detection of Bacterial Endotoxins with the Limulus Amebocyte Lysate Test. New York : Alan R Liss, 1987; 459474.
  • 70
    Nitsche D., Kriewitz M., Rossberg A., et al. The quantitative determination of endotoxin in plasma samples of septic patients with peritonitis using the chromogenic substrate and its correlation with the clinical course of peritonitis. In: WatsonSW, LevinJ., NovitskyTJ (eds.) Detection of Bacterial Endotoxins with the Limulus Amebocyte Lysate Test. New York : Alan R Liss, 1987; 417429.
  • 71
    Brandtzaeg P., Kierulf P., Gaustad P., et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159:195204.
  • 72
    Mathison JC, Ulevitch RJ. The clearance, tissue distribution and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979; 123:21332143.
  • 73
    Freudenberg N., Freudenberg MA, Bandara K., et al.: Distribution and localization of endotoxin in the reticuloendothelial system (RES) and in the main vessels of the rat during shock. Path Res Pract 1985; 179: 517527.
  • 74
    Haeffner-Cavaillon N., Cavaillon JM, Etievant M., et al. Specific binding of endotoxin to human monocytes and mouse macrophages: Serum requirements. Cell Immunol 1985; 91:119131.
  • 75
    Morrison DC. Nonspecific interactions of lipopolysaccharides with membranes and membrane components. In: BerryLJ (ed.) Handbook of Endotoxin, Vol 3: Cellular Biology of Endotoxin. Elsevier Amsterdam , 1985; 25.
  • 76
    Haeffner-Cavallion N., Cavaillon JM, Szabo L. Cellular receptors for endotoxin. In: BerryLJ (ed.) Handbook of Endotoxin, Vol 3: Cellular Biology of Endotoxin. Elsevier: Amsterdam , 1985; 1.
  • 77
    Fox ES, Thomas P., Broitman SA. Comparative studies of endotoxin uptake by isolated rat Kupffer and peritoneal cells. Infect Immun 1987; 55:29622966.
  • 78
    Munford RS. Deacylation of bacterial endotoxins by neutrophils and macrophages: Early observations and hypotheses. Meth and Final Exptl. Clin Pharmacol 1986; 8: 6365.
  • 79
    Doe WF, Yang ST, Morrison DC, et al. Macrophage stimulation by bacterial lipopolysaccharides: II. Evidence for differentiation signals delivered by lipid A and by a protein-rich fraction of lipopolysaccharides: II. Evidence for differentiation signals delivered by lipid A and by a protein-rich fraction of lipopolysaccharides. J Exp Med 1978; 148: 557568.
  • 80
    Dijkstra J., Mellors J. W., Ryan JL, et al. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol 1987; 138:26682670.
  • 81
    Cohn ZA. The activation of mononuclear phagocytes: Fact, fancy and future. J Immunol 1978; 121:813816.
  • 82
    Karnovsky ML, Luzdins JK. Biochemical criteria for activated macrophages. J Immunol 1978; 121:809813.
  • 83
    Adams DO, Hamilton TA. The cell biology of macrophage activation. Ann Rev Immunol 1984; 2:283318.
  • 84
    Johnson RB. Current concepts: Immunology, monocytes and macrophages. N Engl J Med 1988; 318:747752.
  • 85
    Nathan CV. Secretory products of macrophages. J Clin Invest 1987; 79:319326.
  • 86
    Bonney RJ, Humes JL. Physiological and pharmacological regulation of prostaglandin and leukotriene production by macrophages. J Leukoc Biol 1984; 35:110.
  • 87
    Scott WA, Zrike JM, Hammill AI, et al. Regulation of arachidonic acid metabolites in macrophages. J Exp Med 1980; 152:324335.
  • 88
    Scott WA, Pawlowski NA, Andreach M., et al. Resting macrophages produce distinct metabolites from exogenous arachidonic acid. J Exp Med 1982; 155:535547.
  • 89
    Feuerstein N., Ramwell PW. Differential effects of prostaglandin E2 and cyclic AMP on release of arachidonic acid metabolites from resting and LPS-stimulated macrophages. Br J Pharmacol 1984; 83:759762.
  • 90
    Webb PJ, Westwick J., Scully MF, et al. Do prostacyclin and thromboxane play a role in endotoxin shock Br J Surg 1981; 68:720724.
  • 91
    Bottoms GD, Templeton CB, Fessler JF, et al. Thromboxane, prostaglandin I2 (epoprostenol) and the hemodynamic changes in equine endotoxin shock. Am J Vet Res 1982; 43:9991002.
  • 92
    Bottoms GB, Johnson MA, Roessel OF. Endotoxin-induced hemodynamic changes in dogs: Role of thromboxane and prostaglandin I2. Am J Vet Res 1983; 44:14971500.
  • 93
    Slotman GI, Quinn JV, Burchard K.W, et al. Thromboxane, prostacyclin and the hemodynamic effects of graded bacteremic shock. Circ Shock 1985; 16:395404.
  • 94
    Moncado S., Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 1979; 30:392331.
  • 95
    Moore JN, Hardee MM, Hardee GE. Modulation of arachidonic acid metabolism in endotoxin horses: Comparison of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor. Am J Vet Res 1986; 47:110113.
  • 96
    Yellin SA, Nguyen D., Quinn JV, et al. Prostacyclin and thromboxane A2 in septic shock: Species differences. Circ Shock 1986; 20:291297.
  • 97
    Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568575.
  • 98
    Laviolette M., Carreau M., Coulombe R., et al. Metabolism of arachidonic acid through the 5-lipoxygenase pathway in normal human peritoneal macrophages. J Immunol 1988; 141:21042109.
  • 99
    Lefer AM. Significance of lipid mediators in shock states. Circ Shock 1989; 27:312.
  • 100
    Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes CI and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77:43544358.
  • 101
    Hinshaw LB. Release ofvasoactive agents and the vascular effects of endotoxin. In: KadisS., WeinbaumG., AjlSF (eds.) Microbial Toxins. Vol 1. New York : Academic Press, 1981; 209.
  • 102
    Ford-Hutchinson AW, Bray MA, Doig MV, etal. Leukotriene B. a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (London) 1980; 286: 264265.
  • 103
    Bjork J., Arfors KE, Hedquist P., et al. Leukotriene B4 causes leukocyte emigration from postcapillary venules in the hamster cheek pouch. Microcirculation 1982; 3:271281.
  • 104
    Feuerstein N., Foegh M., Ramwell PW. Leukotrienes C4 and D4 induce prostaglandin and thromboxane release from rat peritoneal macrophages. Br J Pharmacol 1981; 72:389391.
  • 105
    Coggeshall JW, Christman BW, Lefferts PJ, et al. Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxin in sheep. J Appl Physiol 1988; 65:13511359.
  • 106
    Applgren CE, Hammorström S. Distribution and metabolism of 3H-labeled leukotriene C3 in the mouse. J Biol Chem 1982; 257:531535.
  • 107
    Hagmann W., Denzlinger C., Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock 1984; 14:223235.
  • 108
    Luderitz TL, Rietschel ET, Schade U. Release of leukotrienes from macrophages stimulated by lipopolysaccharide (endotoxin). Immunobiology 1983; 165:312313.
  • 109
    Luderitz T., Schade U., Rietschel ET. Formation and metabolism of leukotriene C4 in macrophages exposed to bacterial lipopolysaccharide. Eur J Biochem 1986; 155:377382.
  • 110
    Schade UF. Involvement of lipoxygenases in the activation of mouse macrophages by endotoxin. Biochem Biophys Res Commun 1986; 138:842849.
  • 111
    Hagmann W., Keppler D. Leukotriene antagonist prevent endotoxin lethality. Naturwiss 1982; 69:594595.
  • 112
    Cook JA, Wise WC, Halushka PV. Protective effect of a selective leukotriene antagonist in endotoxemia in the rat. J Pharm Exp Ther 1985; 235:470474.
  • 113
    Etemadi AR, Tempel GE, Farah BA, et al. Beneficial effects of a leukotriene antagonist on endotoxin-induced acute hemodynamic alterations. Circ shock 1987; 22:5563.
  • 114
    Dinarello CA. An update on human II-1: From molecular biology to clinical relevance. J Clin Immunol 1985; 5:287297.
  • 115
    Newton RC. Human monocyte production of II-1: Parameters of the induction of II-1 secretion by LPS. J Leuko Biol 1986; 39:299311.
  • 116
    Dinarello CA. Interleukin 1 and the pathogenesis of the acute-phase response. N Engl J Med 1984; 311:14131418.
  • 117
    Baracos V., Rodemann HP, Dinarello CA, et al. Stimulation of muscle protein degradation by leukocytic pyrogen (II-1). N Engl J Med 1983; 308:553558.
  • 118
    Moshage HJ, Janssen JAM, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:16351641.
  • 119
    Cybulsky MI, Colditz IG, Movat HZ. The role of II-1 in neutrophil leukocyte emigration induced by endotoxin. Am J Pathol 1986; 124:367372.
  • 120
    Bevilacqua MP, Pober JS, Wheeler ME, et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest 1985; 76:20032011.
  • 121
    Tracey KS, Lowry SF, Cerami A. Cachectin: A hormone that triggers acute shock and chronic cachexia. J Infect Dis 1988; 157:413420.
  • 122
    Bachwich PR, Chensue SW, Larrick JW, et al. Tumor necrosis factor stimulates II-1 and PGE2 production in resting macrophages. Biochem Biophys Res Commun 1986; 136:94101.
  • 123
    Beutler B., Cerami A. Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316:379385.
  • 124
    Kettelhut IC, Fiers W., Goldberg AI. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 1987; 84:42734277.
  • 125
    Nawroth P., Bunk I., Handley D., et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 1986; 163:13631375.
  • 126
    Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163:14331450.
  • 127
    Gamble JR, Harlan JM, Kelbanoff SJ, et al. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci 1985; 82:86678671.
  • 128
    Stern DM, Nawroth PP. Modulation of endothelial hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740745.
  • 129
    Movat HZ. Tumor necrosis factor and interleukin-1: Role in acute inflammation and microvascular injury. J Lab Clin Med 1987; 668681.
  • 130
    Perimutter DN, Dinarello CA, Pinsal PI. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986; 78:13491354.
  • 131
    Hesse DG, Tracey KJ, Fong Y., et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147153.
  • 132
    Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:14811486.
  • 133
    Tracey KJ, Beutler B., Lowry SF, et al. Shock and tissue injury induced bv recombinant human cachectin. Science 1986; 234:470474.
  • 134
    Tracey KJ, Lowry SF, Fahey TF, et al. Cachectin/tumor necrosis factor induces shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164:415422.
  • 135
    Tracey KJ, Fong Y., Hesse DG, et al. Anti-chacectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330:662664.
  • 136
    Shimamoto Y., Chen RL, Bollon A., et al. Monoclonal antibodies against human recombinant tumor necrosis factor: Prevention of endotoxic shock. Immunol Let 1988; 17:311318.
  • 137
    Kishimoto T. The biology of interleukin-6. Blood 1989; 74:110.
  • 138
    Gauldie J., Richards C., Harnish D., et al. Interferon β2 Bcell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci 1987; 84:72517255.
  • 139
    Poupart P., Vandenabeele P., Cayphas S., et al. Bcell growth modulating and differentiating activity of recombinant human 26-kD protein CBSF.2, Hu IFN-β2, HDGF) EMBO J 1987; 6: 12191224.
  • 140
    Hirano T., Yasakawa K., Haroda H., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:7376.
  • 141
    Castell JV, Gomez-Lechon MJ, David M., et al. Recombinant human interleukin-6 (II-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FESB Lett 1988; 232:347.
  • 142
    Waage A., Brandtzaeg P., Halstensen A., et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333338.
  • 143
    Helfgott DC, Tatter SB, Santhanam V., et al. Multiple forms of IFN-β2 II-6 in serum and body fluids during acute bacterial infection. J Immunol 1989; 142:948953.
  • 144
    Fong Y., Moldawer LL, Marano M., et al. Endotoxemia elicits increased circulating β2-IFN/Il-ö in man. J Immunol 1989; 142:23212324.
  • 145
    Shalaby MR, Waage A., Aarden L., et al. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989; 53:488498.
  • 146
    Edwards RL, Rickles FR. Macrophage procoagulants. Prog Hemostasis Thromb 1984; 7:183209.
  • 147
    Lyberg T. Clinical significance of increased thromboplastin activity on the monocyte surface—A brief review. Haemostasis 1984; 119:6267.
  • 148
    Almdahl SM, Osterud B. Experimental gram-negative septicemia: thromboplastin generation in mononuclear phagocytes from different anatomical sites. Thromb Res 1987; 47:3746.
  • 149
    Henry MM, Moore JN. Endotoxin-induced procoagulant activity in equine peripheral blood monocytes. Circ Shock 1988; 26:297309.
  • 150
    Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79:124130.
  • 151
    Doebber TW, Wu MS, Robbins JC, et al. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats: Studies with PAF-receptor antagonist kadswrenone. Biochem Biophys Res Com 1985; 127:799808.
  • 152
    Toth PD, Mikulaschek AW. Effects of a platelet activating factor antagonist, CV-3988 on different shock models in the rat. Circ Shock 1986; 20:193203.
  • 153
    Camussi G., Aglietta M., Coda R., et al. Release of platelet-activating factor (PAF) and histamine II. The cellular origin of PAF: Monocytes, polymorphonuclear neutrophils, and basophils. Immunology 1981; 42: 191198.
  • 154
    Braquet P., Touqui L., Shen TY, et al. Perspectives in platelet activating factor research. Pharmacol Rev 1987; 39:97145.
  • 155
    Suquet CM, Leid RW. Aggregation of equine platelets by PAF (platelet-activating factor). Inflammation 1983; 7:197203.
  • 156
    O'Flaherty JR, Miller CH, Lewis JC, et al. Neutrophil responses to platelet activating factor. Inflammation 1981; 5:193199.
  • 157
    Hartung HP, Parnham MJ, Winkelmann J., et al. PAF induces the oxidative burst in macrophages. Intl J Immunopharmacol 1983; 5:115121.
  • 158
    Camussi GG, Montrucchio C., Antio C., et al. In vitro spasmogenic effect of platelet-activating factor on rabbit lung tissue. Panminerva Med 1981; 23:179185.
  • 159
    Chignard ML, Couedic JP, Anderson P., et al. Use of steroidal antiinflammatory drug provides further evidence for a potential role of PAF-ascether in bronchial anaphylaxis. Intl Archs Allergy Appl Immunol 1986; 81:184185.
  • 160
    Baranes J., Hellegouarch A., LeHegarat M., et al. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacol Res Commun 1986; 18:717737.
  • 161
    Hundley DA, Lee ML, Saunders RN. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. Thromb Haemostas 1985; 54:756759.
  • 162
    Fuerstein G., Lux WE, Snyder F., et al. Hypotension produced by platelet activating factor is reversed by thyrotropin-releasing hormone. Circ Shock 1984; 13:255260.
  • 163
    Inarrea P., Gomez-Cambronero J., Pascual J., et al. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. Immunopharmacology 1985; 9:4552.
  • 164
    Terashita Z., Imura Y., Nishikawa K., et al. Is platelet activity factor (PAF) a mediator of endotoxin shock Eur J Pharmacol 1985; 109:257261.
  • 165
    Hundley DA, Van Halen RG, Melden MK, et al. Inhibition and reversal of endotoxin aggregated IgG and PAF-induced hypotension in the rat by SRI 63–072, a PAF receptor antagonist. Immunopharmacology 1986; 12:1116.
  • 166
    Armstead WM, Pourcyrous M., Mirro R., et al. Platelet activating factor: A potent constrictor of cerebral arterioles in newborn pigs. Circ Res 1988; 62:17.
  • 167
    Morris DD, Moore JN. Equine peritoneal macrophage production of thromboxane and prostacyclin in response to platelet activating factor and its receptor antagonist SRI 63–441. Circ Shock 1989; 28:149158.
  • 168
    Burhop KE, Vander Zee H., Bizios R., et al. Pulmonary vascular response to PAF in awake sheep and the role of cyclooxygenase metabolites. Am Rev Res Dis 1986; 134:548554.
  • 169
    Coalson JJ, Hinshaw LB, Gunter CA. The pulmonary ultrastructure in septic shock. Exp Mod Pathol 1970; 12:84103.
  • 170
    Snapper JR, Bernard GR, Hinson JM, et al. Endotoxemia induced leukopenia in sheep: Correlation with lung vascular permeability and hypoxemia but not with pulmonary hypertension. Am Rev Res Dis 1983; 127:306309.
  • 171
    Heideman N., Kaijser B., Gelin LE. Complement activation early in endotoxin shock. J Surg Res 1979; 26:74.
  • 172
    Cook JA, Wise WC, Halushka PV. Protective effect of a selective leukotriene antagonist in endotoxemia in the rat. J Pharmacol Exp Ther 1985; 235:470474.
  • 173
    Worthen GS, Haslett C., Smedly LA, et al. Lung vascular injury induced by chemotactic factors: enhancement by bacterial endotoxins. Fed Proc 1986; 45:712.
  • 174
    Quesenberry P., Morley A., Shohlman F., et al. Effect of endotoxin on granulopoiesis and colony stimulating factor. N Engl J Med 1972; 286:227232.
  • 175
    Kaushansky K., Broudy VC, Harlan JM, et al. Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor and II-1 in vivo. J Immunol 1988; 141:34103415.
  • 176
    Bery LJ, Huff WB. Antiglucocorticord effects of endotoxin. Circ Shock 1984; 14:1372265.
  • 177
    Filkins JP. Role of the RES in the pathogenesis of endotoxic hypoglycemia. Circ Shock 1982; 9:269280.
  • 178
    Archer LT. Myocardial dysfunction in endotoxin and E. coli induced shock: Pathophysiologic mechanisms. Circ Shock 1985; 15: 261280.
  • 179
    Salari H. Walker MJA. Cardiac dysfunction caused by factors released from endotoxin-activated macrophages. Circ Shock 1989; 27: 263272.
  • 180
    Flohe L., Giertz H. Endotoxins, arachidonic acid and superoxide formation. Rev Infect Dis 1987; 5:S553S561.
  • 181
    Nathan CF. Secretion of oxygen intermediates: Role in effector functions of activated macrophages. Fed Proc 1982; 41:22062211.
  • 182
    Till GO, Ward PA. Systemic complement activation and acute lung injury. Fed Proc 1986; 45:1318.
  • 183
    Van Steenhouse JL. Free radicals: Relation to tissue damage—A review. Vet Clin Pathol 1987; 16:2935.
  • 184
    Meyrick BO, Ryan US, Brigham KL. Direct effects of E. coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of internal implants. Am J Pathol 1986; 122: 140151.
  • 185
    Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vacular endothelium in vitro. J Clin Invest 1987; 79:124130.
  • 186
    Miossec P., Cavender D., Ziff M. Production of II-1 by human endothelial cells. J Immunol 1986; 136:24862491.
  • 187
    Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:11651172.
  • 188
    Sprenger Ed, KJuft C. Plasminogen activator inhibitors. Blood 1987; 69:381387.
  • 189
    Harlan JM. Leukocyte-endothelial interactions. Blood 1985; 65:513525.
  • 190
    Turek JJ, Lamar CH, Fessler JR, et al. Ultrastructure of equine endothelial cells exposed to endotoxin and flunixin meglumine and equine neutrophils. Am J Vet Res 1987; 48:13631366.
  • 191
    Pabst MJ, Hedegaard HB, Johnston RB Jr. Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response. J Immunol 1982; 128:123128.
  • 192
    Hoover RL, Folger R., Haering WA, et al. Adhesion of leukocytes to endothelium: Roles of divalent cations, surface charge, chemotactic agents and substrate. J Cell Sci 1980; 45:7386.
  • 193
    Libby P., Ordovas JM, Auger KR, et al. Endotoxin and tumor necrosis factor induce interleukin I gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124:179185.
  • 194
    Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94:631636.
  • 195
    Marcum JA, Rosenberg RD. Heparin like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126:365372.
  • 196
    Esmon CT. Protein-C: Biochemistry, physiology and clinical implications. Blood 1983; 62:11551158.
  • 197
    Novotny MJ, Turentine MA, Johnson GS, et al. Experimental endotoxemia increases plasma von Willebrand factor antigen concentrations in dogs with and without free- radical scavenger therapy. Circ Shock 1987; 23:205225.
  • 198
    Bevilacqua MP, Pober JS, Majeau GR, et al. II-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618623.
  • 199
    Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740745.
  • 200
    Guthrie LA, McPhail LC, Henson PM, et al. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial LPS. J Exp Med 1984; 160:16561671.
  • 201
    Haslett C., Guthrie LA, Kopaniak MA, et al. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 1985; 119:101110.
  • 202
    Confer AW, Simmons KR. Effects of Pasteurella hemolytica lipopolysaccharide on selected functions of bovine leukocytes. Am J Vet Res 1986; 47:154157.
  • 203
    Crawford JP, Movat HZ, Minta JO, et al. Acute inflammation induced by immune complexes in the microcirculation. Exp Mol Pathol 1985; 42:175193.
  • 204
    Issekutz AC, Wankowicz Z. Synergy between tumor necrosis factor (TNF alpha) and interleukin 1 (II-1) in the induction of polymorphonuclear leukocyte emigration [abstract] Fed Proc 1987; 46:737.
  • 205
    Janoff A., Carp H. Proteases, antiproteases, and oxidants: Pathways of tissue injury during inflammation. In: MajnoG., CotranRS, KaufmanN. (eds.) Current Topics in Inflammation. Baltimore : Williams and Wilkins, 1982; 6282.
  • 206
    Burrows GE, Cannon J. Endotoxemia induced by rapid intravenous injection of Escherichia coli in anesthetized ponies. Am J Vet Res 1970; 31:19671973.
  • 207
    Burrows GE. Hemodynamic alterations in the anesthetized pony produced by slow intravenous administration of Escherichia coli endotoxin. Am J Vet Res 1970; 31:19751982.
  • 208
    Burrows GE. Escherichia coli endotoxemia in the conscious pony. Am J Vet Res 1971; 32:243248.
  • 209
    Bottoms GD, Fessler JF, Roesel OF, et al. Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. Am J Vet Res 1981; 42:15141518.
  • 210
    Moore JN, Garner HE, Shapland JE, et al. Prevention of endotoxin-induced arterial hypoxemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 1981; 13:9598.
  • 211
    Templeton CB, Bottoms GD, Fessler JF, et al. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: Effects of flunixin meglumine, dexamethasone. and prednisolone. Ci re Shock 1987; 23: 231240.
  • 212
    Fessler JF, Bottoms GD, Roesel OF, et al. Endotoxin-induced changes in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: Effects of flunixin meglumine. Am J Vet Res 1982; 43:140144.
  • 213
    Ewart K., Fessler JF, Templeton CB, et al. Endotoxin-induced hematologic and blood chemical changes in ponies: Effects of flunixin meglumine, dexamethasone, and prednisolone. Am J Vet Res 1985; 46:2430.
  • 214
    Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70:115.
  • 215
    Marder VJ. Consumptive thrombohemorrhagic disorders. In: BuetlerE., ErslevAJ, Lichtman, E. (eds.) Hematology. New York : McGraw-Hill, 1983; 14331461.
  • 216
    Pablo LS, Purohit RC, Teer PA, et al. Disseminated intravascular coagulation in experimental intestinal strangulation obstruction in ponies. Am J Vet Res 1983; 44:21152122.
  • 217
    Johnstone IB, Crane S. Hemostatic abnormalities in equine colic. Am J Vet Res 1986; 47:356358.
  • 218
    Mosher DF. Disorders of blood coagulation. In: WyngaardenJB, SmithLN (eds.) Cecil Textbook of Medicine 18thed. Philadelphia : WB Saunders Co, 1988; 10601081.
  • 219
    Colman RW, Marder VJ. Disseminated intravascular coagulation (DIC): Pathogenesis, pathophysiology, and laboratory abnormalities. In: ColmanRW, HirshJ., MarderVJ, et al, (eds.) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia : JB Lippincott, 1982; 654663.
  • 220
    Bachman F. Fibrinolysis. In: VersraeteM., VermyllenJ., LyjnerR., et al (eds.) Thrombosis and Hemostatis. Leuven , Belgium : Leuven University Press, 1987; 115.
  • 221
    Schleef RR, Bevilacqua MP, Sawdey M., et al. Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J BiolChem 1988; 263:57975803.
  • 222
    Krishnamurti C., Bair CF, Hassett MA, et al. Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69:798803.
  • 223
    Jacobs ER, Bone RC. Clinical indicators in sepsis and septic adult respiratory distress syndrome. Med Clin North Am 1986; 70:921932.
  • 224
    Fry DE. Multiple system organ failure. Surg Clin North Am 1988; 68:107122.
  • 225
    Siegel JH. Relations between circulatory and metabolic changes in sepsis. Annu Rev Med 1981; 32:175194.
  • 226
    Mizock B. Septic shock: A metabolic perspective. Arch Intern Med 1984; 144:579585.
  • 227
    Nelson DP, Samsel RW, Wood LDH, et al. Pathological supply dependence of systemic and intestinal O2 uptake during endotoxemia. J AppI Physiol 1988; 64:24102419.
  • 228
    Clowes GHA, George BC, Villec CA, et al. Muscle proteolysis induced by a circulatory peptide in patients with sepsis or trauma. New Engl J Med 1983; 308:545552.
  • 229
    Dinarello CA, Clowes GHA, Gordon AH, et al. Cleavage of human interleukin-1: Isolation of a peptide fragment from plasma of febrile humans and activated monocytes. J Immunol 1984; 133:13321338.
  • 230
    Freund HR, James JH, LaFrance R., et al. The effect of indomethacin on muscle and liver protein synthesis and whole body protein degradation during abdominal sepsis in the rat. Arch Surg 1986; 121:11541158.
  • 231
    Halushka PV, Cook JA, Wise WC. Beneficial effects of UK-37248, a thromboxane synthetase inhibitor, in experimental endotoxin shock in the rat. Br J Clin Pharmacol 1983; 15:133139.
  • 232
    Teneyama C., Sasao J., Senna S., et al. Protective effects of ONO 3708, a new thromboxane A2 receptor antagonist during experimental endotoxin-shock. Circ Shock 1989; 28:6977.
  • 233
    Fletcher JR, Ramwell PW. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 1980; 7:299308.
  • 234
    Krausz MM, Utsunomiya T., Fenerstein G., et al. Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 1981; 67:11181125.
  • 235
    Parks DA, Bulkley GB, Ganger DN. Role of oxygen free radicals in shock, ischemia and organ preservation. Surgery 1983; 94:428432.
  • 236
    Kunimoto F., Morito T., Ogawa R., et al. Inhibition of lipid peroxidation improves survival rate of endotoxemic rats. Circ Shock 1987; 21:1522.
  • 237
    Wilson R. Etiology, diagnosis and prognosis of positive blood cultures. Am Surg 1981; 47:112115.
  • 238
    Balis JU, Paterson JF, Shelley SA, et al. Glucocorticoid and antibiotic effects of hepatic microcirculation and associated host responses in lethal gram-negative bacteremia. Lab Invest 1979; 40:5565.
  • 239
    Morris DD. Medical management of equine colic. Vet Med 1987; 2:151176.
  • 240
    Ward DS. Fessler JF, Bottoms GD, et al. Equine endotoxemia: cardiovascular, eicosanoid, hematologic, blood chemical and plasma enzyme alterations. Am J Vet Res 1987; 48:11501156.
  • 241
    Moore JN, Garner HE, Shapland JE, et al. Hemodynamic effects of prostacyclin (prostaglandin I2) in conscious ponies. Am J Vet Res 1982; 43:11281131.
  • 242
    Moore JN. Nonsteroidal antiinflammatory drug therapy for endotoxemia: We're doing the right thing, aren't we Comp Cont Educ Pract Vet 1989; 11:741744.
  • 243
    Bottoms GD, Johnson MA, Lamar CH. Endotoxin-induced eicosanoid production by equine vascular endothelial cells and neutrophils. Circ Shock 1985; 15:155162.
  • 244
    Hirata F., Schiffmann E., Venkatasulbramanian K. et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci 1980; 77:25332526.
  • 245
    Pryd H., Lyberg T. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro. Biochem Pharm 1980; 29:914.
  • 246
    Beutler B., Krochin N., Milsark IW. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 1986; 232:977980.
  • 247
    Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653658.
  • 248
    Eyre P., Elmes PJ, Strickland S. Corticosteroid-potentiated vascular responses of the equine digit: a possible pharmacologic basis for laminitis. Am J Vet Res 1979; 40:135138.
  • 249
    Sprung CL, Caralis P., Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984; 311:11371143.
  • 250
    The Vet Administration Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659665.
  • 251
    Moore, JN. The effects of prednisolone sodium succinate in endotoxemia: Comparison with flunixin meglumine. Proceed 1st Equine Colic Res Sympos 1982; 176178.
  • 252
    Moore AB, Roesel OF, Fessler JF, et al. Effects of naloxone on endotoxin-induced changes in ponies. Am J Vet Rev 1983; 44:103109.
  • 253
    Lee HC, Lum BKB. Protective action of calcium entry blockers in endotoxin shock. Circ Shock 1986; 18:193203.
  • 254
    Wilson DD, de Garavilla L., Kuhn W., et al. D-Arg-[Hyp3-D-Phe7]-Bradykinin, a bradykinin antagonist reduces mortality in a rat model of endotoxic shock. Circ Shock 1989; 27:93101.
  • 255
    Schrauwen E., Weyns A., Houvenaghel A. Endotoxin shock in the piglet: beneficial effects of serotonin antagonism. Br Vet J 1985; 141:179185.
  • 256
    Krausz MM, Dahan JB, Gross D. Effect of the leukotriene receptor antagonist LY-171883 on endotoxemia in awake sheep. Circ Shock 1988; 26:431441.
  • 257
    Tate WJ, Douglas H., Braude AI Protection against lethality of Escherichia coli endotoxin with “O” antiserum. Ann NY Acad Sci 1966; 133:744762.
  • 258
    McCabe WR, Bruins SC, Craven DE, et al. Cross-reactive antigens: Their potential for immunization-induced immunity to gram-negative bacteria. J Infect Dis 1977; 136(suppl): 161168.
  • 259
    Braue AI. Endotoxic immunity. Adv Int Med 1980; 26:427445.
  • 260
    McCabe WR. Immunization with R. mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972; 108: 601610.
  • 261
    Ziegler EJ, McCutchan J. A., Douglas N., et al. Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Trans Assoc Am Phys 1975; 88: 101108.
  • 262
    Davis CE, Ziegler EJ, Arnold K. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med 1978; 147:10071017.
  • 263
    Johns M., Skehill A., McCabe WR. Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis 1983; 147: 5767.
  • 264
    Ziegler EJ, McCutchan J. A., Fierrer J., et al. Treatment of gramnegative bacteremia and shock with human antiserum to a mutant E. coli. N Engl J Med 1982; 307: 12251230.
  • 265
    Baumgartner JD, Glauser MP, McCutchan JA, et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 2:5963.
  • 266
    Spier SJ, Lavoie JP, Cullor JS, et al. Protection against clinical endotoxemia in horses using plasma containing antibody to an Re mutant E coli (J5). Circ Shock 1989; 28:235248.
  • 267
    Sprouse RF, Garner HE, Green EM. Active and passive immunization against endotoxemia. Proceed 6th Annu Vet Med Forum 1988; 329331.
  • 268
    Greisman SE, DuBuy JB, Woodward CL. Experimental gramnegative bacterial sepsis: Reevaluation of the ability of rough mutant antisera to protect mice. Proc Soc Exp Biol Med 1978; 158:482490.
  • 269
    Greisman SE, Johnston CA. Failure of antisera to J5 and R 595 rough mutants to reduce endotoxemic lethality. J Infect Dis 1988; 157:5464.
  • 270
    Ng A., Butler Rc, Chen CH, et al. Relationship of structure to function in bacterial endotoxins. IX Differences in the lipid moiety of endotoxic glycolipids. J Bacteriol 1976; 126: 511515.
  • 271
    Peter G., Chernow M., Keating MH, et al. Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia. Infection 1982; 10:228232.
  • 272
    Trautman M., Hahn H. Antiserum against Escherichia coli J5: A re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria. Infection 1985; 3:140145.
  • 273
    Gigliotti F., Shenep JL. Failure of monoclonal antibodies to core glycopilid to bind intact smooth strains of Escherichia coli. J Infect Dis 1985; 151:10051011.
  • 274
    Siber GT, Kania SA, Warren HS. Cross reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli 5 and other gram-negative bacteria. J Infect Dis 1985; 152:954964.
  • 275
    Pollack M., Chin JKS, Koles NL, et al. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis 1989; 159:168188.
  • 276
    Calandra T., Glauser MP, Schellekens J., et al. Treatment of gramnegative shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 1988; 158:312319.
  • 277
    Morris DD, Whitlock RH. Therapy of suspected septicemia in neonatal foals using plasma containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med 1987; 1:175182.
  • 278
    Aldridge MC, Chadwick SJD, Cheslyn-Curtis S., et al. Antibody to endotoxin core glycolipid reverses reticuloendothelial system depression in an animal model of severe sepsis and surgical injury. J Trauma 1987; 27:11661172.
  • 279
    Beutler B., Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869871.
  • 280
    Shimamoto Y., Chen RL, Bollon A., et al. Monoclonal antibodies against human recombinant tumor necrosis factor: Prevention of endotoxic shock. Immunol Let 1988; 17:311318.
  • 281
    Tracey K.J, Fong Y., Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662664.
  • 282
    Nagai M., Saigusa T., Shimada Y., et al. Antibody to tumor necrosis factor (TNF) reduces endotoxin fever. Experimentia 1988; 44:606607.
  • 283
    Morris DD, Crowe N., Moore JN. Serum tumor necrosis factor activity in horses during experimental endotoxemia: Correlation with clinical and laboratory signs. Am J Vet Res 1990, in press.
  • 284
    Morris DD, Henry MM, Moore JN, et al. Effect of dietary linolenic acid on endotoxin-induced thromboxane and prostacyclin production by equine peritoneal macrophages. Circ Shock 1989; 29:311318.
  • 285
    Morris DD, Henry MM, Moore JN, et al. Dietary alpha linolenic acid reduces endotoxin-induced production of tumor necrosis factor by equine peritoneal macrophages. Am J Vet Res (in press).